ClinicalTrials.gg
RecruitingNCT04372875Updated Mar 18, 2026

Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial

An interventional study of SHS-derived CDS in Sexually Transmitted Diseases, sponsored by Children's National Research Institute. Recruiting at 1 site in United States. Open to participants aged 15 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Children's National Research Institute · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18,500
Allocation
Non-randomized
Ages
15 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.

Planned enrollment
5th of 251
18,500 · median 400
Started
2023
with 13 others
No phase
190 of 283
24 open now
Primary completion
2026-12
later than 10 of 41 live
Registered
209th of 283
by date

Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 5th largest by planned enrollment of the 251 interventional ones that give a count, is one of 14 that started in 2023, is one of 190 with no phase, reaches primary completion later than 10 of the 41 other live ones, and was the 209th registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: 15 Years to 21 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Sexually Transmitted Diseases with a site in United States, or all of them as a file.
02

Study summary

We will compare differences in sexually transmitted infection (STI) detection rates between sexual health survey (SHS)-derived electronic clinical decision support (CDS) versus usual care (e.g. no provision of CDS) using an interrupted time series design. We hypothesize that population-based STI detection rates will be higher when SHS-derived electronic CDS is provided compared to usual care. Secondary analysis will include a comparison of STI detection rates by sexual risk strata (high risk vs. at risk) and race/ethnicity.

03

Conditions studied

  • Sexually Transmitted Diseases
04

Who can participate

Ages eligible
15 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents aged 15-21 years seeking care in the emergency department

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded if unable to understand English, are critically ill, cognitively impaired, or otherwise unable to provide consent for completion of the sexual health survey (SHS) and STI screening.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18,500 participants (estimated)

Study arms

  • Experimental
    SHS-derived CDS

    All adolescents seen in the emergency department that meet eligibility criteria will be offered the sexual health survey (SHS) during the pragmatic trial.

    Behavioral: SHS-derived CDS

  • No intervention
    Usual care

    All adolescents seen in the emergency department that meet eligibility criteria prior to implementation of SHS-derived CDS.

Interventions

  • BehavioralSHS-derived CDS

    This intervention will provide electronic clinical decision support for adolescents who screen at risk or at high risk of an STI.

06

What researchers measure

Primary outcomes

  1. Chlamydia trachomatis (CT) / Neisseria gonorrhoeae (GC) detection rates

    Proportion of encounters during which patients test positive for CT/GC; measured by urine-based nucleic acid amplification tests.

    Time frame: 3-7 days after emergency department (ED) visit

Secondary outcomes

  1. STI rates by race/ethnicity

    Change in STI rates by race/ethnicity

    Time frame: 3-7 days after ED visit

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's planned 45 months is above that.

Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2020
First posted
May 4, 2020
StartActual
Mar 8, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 15, 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04372875
Responsible party
Monika Goyal (Associate Professor of Pediatrics and Emergency Medicine, Children's National Research Institute) — Principal investigator
First posted
May 4, 2020
Start date
Mar 8, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Meleah Boyle
Contact
mdboyle@childrensnational.org
2024765388
Monika Goyal, MD
Contact
mgoyal@cnmc.org
12024762869

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion